Ethical implications of preclinical studies

Animal experiments are fundamental for the biomedical science. The development of new drugs is always associated with a large number of preclinical experiments in animals. Experimental data make it possible to predict the drug efficacy and safety in humans. There are more than 100 million laboratory animals that are used by researchers every year worldwide. This fact raises a number of concerns regarding the legality and ethical appropriateness of using such a large number of animals. This article discusses the problem of using an unreasonably large number of experimental animals during preclinical drug studies, as well as potential ways of streamlining existing methods used for determining the acute and subacute toxicity of drugs in order to minimize the time of the study and the number of animals used. In addition, we review the problem of systematizing experimental data and potential ways of their standardization in line with the European legislation regulating ethically approved use of animals in experiments.

доклинические испытания, разработка и поиск новых лекарственных средств, острая токсичность, эксперименты на животных, этическое регулирование, preclinical trials, development of new medicines, acute toxicity, experiments on animals, ethical regulation

1. Khabriev EN, ed. Manual on experimental (preclinical) study of new pharmacological substances. 2nd ed., rev. and add. Moscow: Medicine; 2005. 832 p. (in Russian)

2. Kurzanov AN. Bioethical aspects of research and educational activities in medical research institutes and universities. Fundamental issled. 2009; (2): 92–3 (in Russian).

3. Karkischenko NN. Basics biomodeling. Moscow: Izd-vo VPK; 2004. 607 p. (in Russian)

4. Karkischenko NN. Alternatives to biomedicine. Vol. 1. Fundamentals of biomedical and pharmacological modeling. Moscow: Izd-vo VPK; 2007. 320 p. (in Russian).

5. Karkischenko NN., ed. Laboratory animals. Regulations and guidance. Moscow: Izd-vo VPK; 2003. 138 p. (in Russian).

6. Festing MFW. Good experimental design and statistics can save animals, but how can it be promoted? ATLA 2004; 32 (suppl. 1A): 133–6.

7. Karkischenko NN. Classic and alternative models of drug toxicology. Biomed. 2006 (4): 5–23. (in Russian)

8. OECD. OECD Guidelines for the Testing of Chemicals: Acute Oral Toxicity – Fixed Dose Procedure. Paris, France: Organization for Economic Cooperation and Development; 2001. P. 115–136.

9. OECD. OECD Guidelines for the Testing of Chemicals No.: Acute Toxic Class Method. Paris, France: Organization for Economic Cooperation and Development; 2001. P. 423.

10. OECD. OECD Guidelines for the Testing of Chemicals: Acute Oral Toxicity – Up- and-Down Procedure. Paris, France: Organization for Economic Cooperation and Development; 2001. P. 425.

11. Petrov VI, Sedov NN. Practical bioethics: ethical committees in Russia: monograf. nauch. izd. Moscow: Triumf; 2002. 192 p. (in Russian).

12. Singh D, Gawande D, Singh T, Poroikov V, Goel RK. Revealing pharmacodynamics of medicinal plants using in silico approach: A case study with wet lab validation. Comp Biol Med. 2014; 47 (1): 1–6.

13. Filz OA, Poroikov VV. Construction of molecules with desired properties using libraries of structural fragments. Uspechi chimii 2012; 81 (2): 158–74 (in Russian).

14. Ibragimova KD, Yakovlev DS, Vasilyev PM. Analysis of the in silico search capabilities purine receptor selective ligands. Vestn Volgograd gos med univer. 2014; (5): 47–8 (in Russian).

15. Vasilyev PM, Spasov AA, Lenskaya KV, Poroikov VV, Filimonov DA, Anisimov VA. Planning in silico screening and experimental study of cyclic guanidine derivatives hypoglycemic. Kubansk nauch med vestn. 2014; 6 (148): 11–5 (in Russian).

16. Thomsen R, Christensen M. MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006; 49 (11): 3315–21.